Riskpilot← Back to searchSign inGet full accessTransient Pharma AB
ABActiveOrg 5592007875Medicon Village Scheeletorget 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20190 employees
Revenue 2024
SEK 0
EBITDA margin
—
-22123% vs 2023
Equity ratio
93.4%
Financial strength
Net profit 2024
SEK -1,9M
-28535% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -2,2M | -22123% |
| Net profit | SEK -1,9M | -28535% |
| Total assets | SEK 14M | +10549% |
| Equity | SEK 13,1M | +9847% |
| Employees | 0 | — |
Legal name
Transient Pharma AB
Org number
5592007875
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 april 2019
Share capital
SEK 70 001
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av Jensen, Johan Mikael i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva medicinsk forskning och utveckling, äga och förvalta fast och lös egendom samt därmed förenlig verksamhet.
Address
Medicon Village Scheeletorget 1
Email
helene.hartman@transientpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | −0 | — | −16 |
| EBITDA | −1 | −7 | 96 | −0 | −10 | −2 182 |
| Depreciation & amort. | −0 | −0 | −0 | — | — | — |
| EBIT | −1 | −7 | 96 | −0 | −10 | −2 182 |
| Net financials | — | — | — | 0 | 3 | 274 |
| Profit before tax | −1 | −7 | 96 | 0 | −7 | −1 908 |
| Tax | −0 | −0 | −0 | — | — | — |
| Net profit | −1 | −7 | 96 | 0 | −7 | −1 908 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 49 | 43 | 138 | 189 | 132 | 14 040 |
| Equity | 49 | 43 | 138 | 139 | 132 | 13 114 |
| Long-term debt | 0 | 0 | 0 | — | — | — |
| Short-term debt | 0 | 0 | 0 | 50 | 0 | 926 |
| Total debt | — | — | — | 50 | — | 926 |
EBITDA margin
-218204200.0%
This company
15.8%
Market median
-1381039341% vs market
20192024
Equity ratio
93.4%
This company
38.2%
Market median
+145% vs market
20192024
Return on equity
-14.5%
This company
18.4%
Market median
-179% vs market
20192024
Net profit margin
-190797800.0%
This company
8.1%
Market median
-2355528495% vs market
20192024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20192024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-04-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MH Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
BU | Audit | 2020 | — | — |
LJ Auditor Substitute | Auditor Substitute | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Transient Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Helene Lilian Hartman | Chief Executive Officer | 0 companies |
| Bertil Ulf Moritz Raue | Audit | 0 companies |
| Lars Joakim Leifland | Auditor Substitute | 0 companies |
| Annette Carina Mattsson | Board of Directors | 0 companies |
| Bo Ture David Benell | Chairman | 0 companies |
| Lena Mårtensson Wernrud | Board of Directors | 0 companies |
| Johan Mikael Jensen | Board of Directors | 0 companies |
| Artur Schmidtchen | Board of Directors | 0 companies |